Abstract
Chronic hepatitis C virus (HCV) infection is associated with an increase in hepatic steatosis and a decrease in serum levels of total cholesterol, low-density lipoprotein cholesterol (LDL) and apolipoprotein B (apoB), the main protein constituent of LDL and very low-density lipoprotein (VLDL). These changes are more marked in HCV genotype 3 infection, and effective treatment results in their reversal. Low lipid levels in HCV infection correlate not only with steatosis and more advanced liver fibrosis but also with non-response to interferon-based therapy. The clinical relevance of disrupted lipid metabolism reflects the fact that lipids play a crucial role in the life cycle of hepatitis C virus. HCV assembly and maturation in hepatocytes depend on microsomal triglyceride transfer protein and apoB in a manner that parallels the formation of VLDL. VLDL production from the liver occurs throughout the day with an estimated 1018 particles produced every 24 h whilst the estimated hepatitis C virion production rate is 1012 virions per day. HCV particles in the serum exist as a mixture of complete low-density infectious lipo-viral particles (LVP) and a vast excess of apoB-associated empty nucleocapsid-free sub-viral particles that are complexed with anti-HCV envelope antibodies. Apolipoprotein E (apoE) is also involved in HCV particle morphogenesis and is an essential apolipoprotein for HCV infectivity. ApoE is a critical ligand for the receptor-mediated removal of triglyceride rich lipoprotein (TRL) remnants by the liver. The dynamics of apoB-associated lipoproteins, including HCV-LVP, change post-prandially with an increase in large TRL remnants and very low density HCV-LVP which are rapidly cleared by the liver (at least three HCV receptors are cellular receptors for uptake of TRL remnants). In summary, HCV utilises triglyceride-rich lipoprotein pathways within the liver and the circulation to its advantage.
Similar content being viewed by others
References
Blasiole DA, Davis RA, Attie AD (2007) The physiological and molecular regulation of lipoprotein assembly and secretion. Mol Biosyst 3(9):608–619
Alter MJ (2007) Epidemiology of hepatitis C virus infection. World J Gastroenterol 13(17):2436–2441
Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP (2006) The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45(4):529–538
Simmonds P (2004) Genetic diversity and evolution of hepatitis C virus—15 years on. J Gen Virol 85(Pt 11):3173–3188
Neumann AU, Lam NP, Dahari H et al (1998) Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282(5386):103–107
Simmonds P, Bukh J, Combet C et al (2005) Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42(4):962–973
Jang JY, Chung RT (2011) Chronic hepatitis C. Gut and liver 5(2):117–132
Pang PS, Planet PJ, Glenn JS (2009) The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy. PLoS One 4(8):e6579
Virgin HW, Wherry EJ, Ahmed R (2009) Redefining chronic viral infection. Cell 138(1):30–50
Wakita T, Pietschmann T, Kato T et al (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11(7):791–796
Podevin P, Carpentier A, Pene V et al (2010) Production of infectious hepatitis C virus in primary cultures of human adult hepatocytes. Gastroenterology 139(4):1355–1364
Aly HH, Oshiumi H, Shime H et al (2011) Development of mouse hepatocyte lines permissive for hepatitis C virus (HCV). PLoS One 6(6):e21284
Bassendine MF, Sheridan DA, Felmlee DJ et al (2011) HCV and the hepatic lipid pathway as a potential treatment target. J Hepatol 55(6):1428–1440
Bamber M, Murray AK, Weller IV et al (1981) Clinical and histological features of a group of patients with sporadic non-A, non-B hepatitis. J Clin Pathol 34(10):1175–1180
Goodman ZD, Ishak KG (1995) Histopathology of hepatitis C virus infection. Semin Liver Disease 15(1):70–81
Czaja AJ, Carpenter HA, Santrach PJ, Moore SB (1998) Host- and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol 29(2):198–206
Mihm S, Fayyazi A, Hartmann H, Ramadori G (1997) Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Hepatology 25(3):735–739
Adinolfi LE, Utili R, Andreana A et al (2000) Relationship between genotypes of hepatitis C virus and histopathological manifestations in chronic hepatitis C patients. Eur J Gastroenterol Hepatol 12(3):299–304
Rubbia-Brandt L, Quadri R, Abid K et al (2000) Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 33(1):106–115
Kumar D, Farrell GC, Fung C, George J (2002) Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology 36(5):1266–1272
Castera L, Hezode C, Roudot-Thoraval F et al (2004) Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Gut 53(3):420–424
Poynard T, Ratziu V, McHutchison J et al (2003) Effect of treatment with peginterferon or interferon alpha-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 38(1):75–85
Baiocchi L, Tisone G, Palmieri G et al (1998) Hepatic steatosis: a specific sign of hepatitis C reinfection after liver transplantation. Liver Transpl Surg 4(6):441–447
Lerat H, Honda M, Beard MR et al (2002) Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 122(2):352–365
Moriya K, Yotsuyanagi H, Shintani Y et al (1997) Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 78(Pt 7):1527–1531
Piodi A, Chouteau P, Lerat H, Hezode C, Pawlotsky JM (2008) Morphological changes in intracellular lipid droplets induced by different hepatitis C virus genotype core sequences and relationship with steatosis. Hepatology 48(1):16–27
Herker E, Harris C, Hernandez C et al (2010) Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1. Nat Med 16:1295–1298
Harris C, Herker E, Farese RV Jr, Ott M (2011) Hepatitis C virus core protein decreases lipid droplet turnover: a mechanism for core-induced steatosis. J Biol Chem 286(49):42615–42625
Tachi Y, Katano Y, Honda T et al (2010) Impact of amino acid substitutions in the hepatitis C virus genotype 1b core region on liver steatosis and hepatic oxidative stress in patients with chronic hepatitis C. Liver Int 30(4):554–559
Miyoshi H, Moriya K, Tsutsumi T et al (2011) Pathogenesis of lipid metabolism disorder in hepatitis C: polyunsaturated fatty acids counteract lipid alterations induced by the core protein. J Hepatol 54(3):432–438
Vescovo T, Romagnoli A, Perdomo AB et al (2012) Autophagy protects cells from HCV-induced defects in lipid metabolism. Gastroenterology 142:644–653
Hourigan LF, Macdonald GA, Purdie D et al (1999) Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 29(4):1215–1219
Adinolfi LE, Gambardella M, Andreana A et al (2001) Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 33(6):1358–1364
Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL (2002) Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 36(3):729–736
Perumalswami P, Kleiner DE, Lutchman G et al (2006) Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. Hepatology 43(4):780–787
Negro F, Sanyal AJ (2009) Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data. Liver Int 29(Suppl 2):26–37
Fernandez-Hernando C, Suarez Y, Rayner KJ, Moore KJ (2011) MicroRNAs in lipid metabolism. Curr Opin Lipidol 22(2):86–92
Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L (2011) Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 6(8):e23937
Mallat A, Lotersztajn S (2010) Endocannabinoids and their role in fatty liver disease. Dig Dis 28(1):261–266, Basel, Switzerland
Toyoda M, Kitaoka A, Machida K et al (2011) Association between lipid accumulation and the cannabinoid system in Huh7 cells expressing HCV genes. Int J Molec Med 27(5):619–624
Romeo S, Kozlitina J, Xing C et al (2008) Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40(12):1461–1465
Trepo E, Pradat P, Potthoff A et al (2011) Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology 54(1):60–69
Valenti L, Rumi M, Galmozzi E et al (2011) Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology 53(3):791–799
Cai T, Dufour JF, Muellhaupt B et al (2011) Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosis. J Hepatol 55(3):529–535
Leandro G, Mangia A, Hui J et al (2006) Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 130(6):1636–1642
Hu KQ, Currie SL, Shen H et al (2007) Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans. Dig Dis Sci 52(2):570–578
Marks KM, Petrovic LM, Talal AH et al (2005) Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus. J Infect Dis 192(11):1943–1949
McGovern BH, Ditelberg JS, Taylor LE et al (2006) Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis 43(3):365–372
Brandman D, Pingitore A, Lai JC et al (2011) Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus. Liver Transpl 17(12):1380–1386
Bugianesi E, Marchesini G, Gentilcore E et al (2006) Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: role of insulin resistance and hepatic steatosis. Hepatology 44(6):1648–1655
Soresi M, Tripi S, Franco V et al (2006) Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis. Liver Int 26(9):1119–1125
Westin J, Lagging M, Dhillon AP et al (2007) Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. J Viral Hepatitis 14(1):29–35
Lok AS, Everhart JE, Chung RT et al (2007) Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol 5(2):245–254
Shah SR, Patel K, Marcellin P et al (2011) Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3. Clin Gastroenterol Hepatol 9(8):688–693
Pekow JR, Bhan AK, Zheng H, Chung RT (2007) Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer 109(12):2490–2496
Lerat H, Higgs M, Pawlotsky JM (2011) Animal models in the study of hepatitis C virus-associated liver pathologies. Expert Rev Gastroenterol Hepatol 5(3):341–352
Perlemuter G, Sabile A, Lettteron P et al (2002) Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 16(2):185–194
Moriya K, Fujie H, Shintani Y et al (1998) The core protein of hepatitis C virus induces hepatocellular carcinmoa in transgenic mice. Nature Med 4(9):1065–1067
Ahmad J, Eng FJ, Branch AD (2011) HCV and HCC: clinical update and a review of HCC-associated viral mutations in the core gene. Semin Liver Disease 31(4):347–355
Maggi G, Bottelli R, Gola D et al (1996) Serum cholesterol and chronic hepatitis C. Ital J Gastroenterol 28(8):436–440
Fabris C, Federico E, Soardo G, Falleti E, Pirisi M (1997) Blood lipids of patients with chronic hepatitis: differences related to viral etiology. Clin Chim Acta; Int J Clin Chem 261(2):159–165
Polgreen PM, Fultz SL, Justice AC et al (2004) Association of hypocholesterolaemia with hepatitis C virus infection in HIV-infected people. HIV medicine 5(3):144–150
Hofer H, Banki HC, Wrba F et al (2002) Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. Am J Gastroenterol 97(11):2880–2885
Sheridan DA, Price DA, Schmid ML et al (2009) Apolipoprotein B-associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti-viral agents interferon-alpha and ribavirin. Aliment Pharmacol Ther 29(12):1282–1290
Moriya K, Shintani Y, Fujie H et al (2003) Serum lipid profile of patients with genotype 1b hepatitis C viral infection in Japan. Hepatol Res 25(4):371–376
Marzouk D, Sass J, Bakr I et al (2007) Metabolic and cardiovascular risk profiles and hepatitis C virus infection in rural Egypt. Gut 56(8):1105–1110
Dai CY, Chuang WL, Ho CK et al (2008) Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study. J Hepatol 49(1):9–16
Miyazaki T, Honda A, Ikegami T et al (2011) Hepatitis C virus infection causes hypolipidemia regardless of hepatic damage or nutritional state: an epidemiological survey of a large Japanese cohort. Hepatol Res 41(6):530–541
Lao XQ, Thompson A, McHutchison JG, McCarthy JJ (2011) Sex and age differences in lipid response to chronic infection with the hepatitis C virus in the United States National Health and Nutrition Examination Surveys. J Viral hepatitis 18(8):571–579
Arciello M, Petta S, Leoni V et al (2012) Inverse correlation between plasma oxysterol and LDL-cholesterol levels in hepatitis C virus-infected patients. Dig Liver Dis 44(3):245–250
Corey KE, Kane E, Munroe C et al (2009) Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology 50(4):1030–1037
Corey KE, Mendez-Navarro J, Barlow LL et al (2011) Acute hepatitis C infection lowers serum lipid levels. J Viral hepatitis 18(7):e366–e371
Serfaty L, Andreani T, Giral P et al (2001) Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 34(3):428–434
Petit JM, Benichou M, Duvillard L et al (2003) Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis. Am J Gastroenterol 98(5):1150–1154
Bima AI, Hooper AJ, van Bockxmeer FM, Burnett JR (2009) Hypobetalipoproteinaemia secondary to chronic hepatitis C virus infection in a patient with familial hypercholesterolaemia. Ann Clin Biochem 46(Pt 5):420–422
Domitrovich AM, Felmlee DJ, Siddiqui A (2005) Hepatitis C virus nonstructural proteins inhibit apolipoprotein B100 secretion. J Biol Chem 280(48):39802–39808
Rowell J, Thompson AJ, Guyton JR et al (2011) Serum apolipoprotein C-III is independently associated with chronic hepatitis C infection and advanced fibrosis. Hepatol Int Jul 7 [Epub ahead of print]
Gangadharan B, Bapat M, Rossa J et al (2012) Discovery of novel biomarker candidates for liver fibrosis in hepatitis C patients: a preliminary study. PLoS One 7(6):e39603
Sheridan DA, Bridge SH, Felmlee DJ et al (2012) Apolipoprotein-E and hepatitis C lipoviral particles in genotype 1 infection: evidence for an association with interferon sensitivity. J Hepatol 57(1):32–38
Fernadez-Rodriguez CM, Lopez-Serrano P, Alonso S et al (2006) Long-term reversal of hypocholesterolaemia in patients with chronic hepatitis C is related to sustained viral response and viral genotype. Aliment Pharmacol Ther 24(3):507–512
Afdhal NH, McHutchison JG, Zeuzem S et al (2011) Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology 53(1):336–345
Li JH, Lao XQ, Tillmann HL et al (2010) Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology 51(6):1904–1911
Aizawa Y, Yohizawa K, Aida Y et al (2012) Genotype rs8099917 near the IL28B gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum apolipoprotein B-100 concentration in chronic hepatitis C. Mol Cell Biochem 360(1–2):9–14
Tillmann HL, Patel K, Muir AJ et al (2011) Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. J Hepatol 55(6):1195–1200
Ramcharran D, Wahed AS, Conjeevaram HS et al (2011) Serum lipids and their associations with viral levels and liver disease severity in a treatment-naive chronic hepatitis C type 1-infected cohort. J Viral hepatitis 18(4):e144–e152
Backus LI, Boothroyd DB, Phillips BR, Mole LA (2007) Predictors of response of US Veterans to treatment for the hepatitis C virus. Hepatology 46(1):37–47
Lange CM, von Wagner M, Bojunga J et al (2010) Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-alpha-2a and ribavirin. Eur J Gastroenterol Hepatol 22(11):1303–1307
Gopal K, Johnson TC, Gopal S et al (2006) Correlation between beta-lipoprotein levels and outcome of heaptitis C treatment. Hepatology 44:335–340
Akuta N, Suzuki F, Kawamura Y et al (2007) Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 46(3):403–410
Harrison SA, Rossaro L, Hu KQ et al (2010) Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology 52(3):864–874
del Valle J, Mira JA, de los Santos I et al (2008) Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients. AIDS 22(8):923–930
Cesari M, Caramma I, Antinori S et al (2009) Impact of hyperglycaemia and cholesterol levels on the outcome of hepatitis C virus (HCV) treatment in HIV/HCV-coinfected patients. HIV medicine 10(9):580–585
Mostafa A, Mohamed MK, Saeed M et al (2010) Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors. Gut 59(8):1135–1140
Alyan O, Kacmaz F, Ozdemir O et al (2008) Hepatitis C infection is associated with increased coronary artery atherosclerosis defined by modified Reardon severity score system. Circ J 72(12):1960–1965
Butt AA, Xiaoqiang W, Budoff M et al (2009) Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis 49(2):225–232
Oliveira CP, Kappel CR, Siqueira ER et al (2011) effects of hepatitis c virus on cardiovascular risk in infected patients: a comparative study. Int J Cardiol Jul 22 [Epub ahead of print]
Petta S, Torres D, Fazio G et al (2012) Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations. Hepatology 55(5):1317–1323
Bedimo R, Westfall AO, Mugavero M et al (2010) Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. HIV medicine 11(7):462–468
Weber R, Sabin C, Reiss P et al (2010) HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study. Antivir Ther 15(8):1077–1086
Eslam M, Khattab MA, Harrison SA (2011) Insulin resistance and hepatitis C: an evolving story. Gut 60(8):1139–1151
Sundaram M, Yao Z (2010) Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion. Nutr Metab 7:35
Hussain MM, Shi J, Dreizen P (2003) Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J Lipid Res 44:22–32
Rutledge AC, Su Q, Adeli K (2010) Apolipoprotein B100 biogenesis: a complex array of intracellular mechanisms regulating folding, stability, and lipoprotein assembly. Biochemistry and cell biology =. Biochim Biol Cell 88(2):251–267
Olofsson SO, Bostrom P, Andersson L et al (2009) Lipid droplets as dynamic organelles connecting storage and efflux of lipids. Biochim Biophys Acta 1791(6):448–458
Sundaram M, Zhong S, Bou Khalil M et al (2010) Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions. J Lipid Res 51(1):150–161
Sorensen LP, Andersen IR, Sondergaard E et al (2011) Basal and insulin mediated VLDL-triglyceride kinetics in type 2 diabetic men. Diabetes 60(1):88–96
Adiels M, Olofsson SO, Taskinen MR, Boren J (2008) Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 28(7):1225–1236
Wang L, Walsh MT, Small DM (2006) Apolipoprotein B is conformationally flexible but anchored at a triolein/water interface: a possible model for lipoprotein surfaces. Proc Natl Acad Sci U S A 103(18):6871–6876
Packard CJ, Munro A, Lorimer AR, Gotto AM, Shepherd J (1984) Metabolism of apolipoprotein B in large triglyceride-rich very low density lipoproteins of normal and hypertriglyceridemic subjects. J Clin Investig 74(6):2178–2192
Lund-Katz S, Phillips MC (2010) High density lipoprotein structure-function and role in reverse cholesterol transport. Sub-cell Biochem 51:183–227
Vaisar T, Pennathur S, Green PS et al (2007) Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Investig 117(3):746–756
Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT (2011) MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 13(4):423–433
Moradpour D, Penin F, Rice CM (2007) Replication of hepatitis C virus. Nat Rev Microbiol 5(6):453–463
Alvisi G, Madan V, Bartenschlager R (2011) Hepatitis C virus and host cell lipids: an intimate connection. RNA Biol 8(2):258–269
Egger D, Wolk B, Gosert R et al (2002) Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol 76(12):5974–5984
Gosert R, Egger D, Lohmann V et al (2003) Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J Virol 77(9):5487–5492
Tai AW, Benita Y, Peng LF et al (2009) A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe 5(3):298–307
Lim YS, Hwang SB (2011) Hepatitis C virus NS5A protein interacts with phosphatidylinositol 4-kinase type IIIalpha and regulates viral propagation. J Biol Chem 286(13):11290–11298
Berger KL, Kelly SM, Jordan TX, Tartell MA, Randall G (2011) Hepatitis C virus stimulates the phosphatidylinositol 4-kinase III alpha-dependent phosphatidylinositol 4-phosphate production that is essential for its replication. J Virol 85(17):8870–8883
Wang C, Gale M Jr, Keller BC et al (2005) Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Molecular cell 18(4):425–434
Kapadia SB, Chisari FV (2005) Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci U S A 102(7):2561–2566
Leu GZ, Lin TY, Hsu JT (2004) Anti-HCV activities of selective polyunsaturated fatty acids. Biochem Biophys Res Commun 318(1):275–280
Roberts AP, Lewis AP, Jopling CL (2011) miR-122 activates hepatitis C virus translation by a specialized mechanism requiring particular RNA components. Nucleic Acids Res 39(17):7716–7729
Krutzfeldt J, Rajewsky N, Braich R et al (2005) Silencing of microRNAs in vivo with ‘antagomirs’. Nature 438(7068):685–689
Esau C, Davis S, Murray SF et al (2006) miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 3(2):87–98
Lanford RE, Hildebrandt-Eriksen ES, Petri A et al (2010) Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327(5962):198–201
Huang H, Sun F, Owen DM et al (2007) Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci U S A 104(14):5848–5853
Nahmias Y, Goldwasser J, Casali M et al (2008) Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. Hepatology 47(5):1437–1445
Gastaminza P, Cheng G, Wieland S et al (2008) Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J Virol 82(5):2120–2129
Ndongo-Thiam N, Berthillon P, Errazuriz E et al (2011) Long-term propagation of serum hepatitis C virus (HCV) with production of enveloped HCV particles in human HepaRG hepatocytes. Hepatology 54(2):406–417
Icard V, Diaz O, Scholtes C et al (2009) Secretion of hepatitis C virus envelope glycoproteins depends on assembly of apolipoprotein B positive lipoproteins. PLoS One 4(1):e4233
Barba G, Harper F, Harada T et al (1997) Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci U S A 94(4):1200–1205
Rouille Y, Helle F, Delgrange D et al (2006) Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus. J Virol 80(6):2832–2841
Miyanari Y, Atsuzawa K, Usuda N et al (2007) The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 9(9):1089–1097
Targett-Adams P, Hope G, Boulant S, McLauchlan J (2008) Maturation of hepatitis C virus core protein by signal peptide peptidase is required for virus production. J Biol Chem 283(24):16850–16859
Counihan NA, Rawlinson SM, Lindenbach BD (2011) Trafficking of hepatitis C virus core protein during virus particle assembly. PLoS Pathog 7(10):e1002302
Jones DM, McLauchlan J (2010) Hepatitis C virus: assembly and release of virus particles. J Biol Chem 285(30):22733–9
Coller KE, Heaton NS, Berger KL et al (2012) Molecular determinants and dynamics of hepatitis C virus secretion. PLoS Pathog 8(1):e1002466
Li Q, Brass AL, Ng A et al (2009) A genome-wide genetic screen for host factors required for hepatitis C virus propagation. Proc Natl Acad Sci U S A 106(38):16410–16415
Jiang J, Luo G (2009) Apolipoprotein E but not B is required for the formation of infectious hepatitis C virus particles. J Virol 83(24):12680–12691
Cun W, Jiang J, Luo G (2010) The C-terminal alpha-helix domain of apolipoprotein E is required for interaction with nonstructural protein 5A and assembly of hepatitis C virus. J Virol 84(21):11532–11541
Benga WJ, Krieger SE, Dimitrova M et al (2010) Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles. Hepatology 51(1):43–53
Long G, Hiet MS, Windisch MP et al (2011) Mouse hepatic cells support assembly of infectious hepatitis C virus particles. Gastroenterology 141(3):1057–1066
Nielsen SU, Bassendine MF, Martin C et al (2008) Characterization of hepatitis C RNA-containing particles from human liver by density and size. J Gen Virol 89(10):2507–2517
Blackham S, Baillie A, Al-Hababi F et al (2010) Gene expression profiling indicates the roles of host oxidative stress, apoptosis, lipid metabolism, and intracellular transport genes in the replication of hepatitis C virus. J Virol 84(10):5404–5414
Yang W, Hood BL, Chadwick SL et al (2008) Fatty acid synthase is up-regulated during hepatitis C virus infection and regulates hepatitis C virus entry and production. Hepatology 48(5):1396–1403
Woodhouse SD, Narayan R, Latham S et al (2010) Transcriptome sequencing, microarray, and proteomic analyses reveal cellular and metabolic impact of hepatitis C virus infection in vitro. Hepatology 52(2):443–453
Roe B, Kensicki E, Mohney R, Hall WW (2011) Metabolomic profile of hepatitis C virus-infected hepatocytes. PLoS One 6(8):e23641
Bukh J (2004) A critical role for the chimpanzee model in the study of hepatitis C. Hepatology 39(6):1469–1475
Lindenbach BD, Evans MJ, Syder AJ et al (2005) Complete replication of hepatitis C virus in cell culture. Science 309(5734):623–626
Andre P, Komurian PF, Deforges S et al (2002) Characterization of low- and very-low-density hepatitis C virus RNA containing particles. J Virol 76:6919–6928
Nielson SU, Bassendine MF, Burt AD et al (2006) Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analysed in iodixanol density gradients. J Virol 80(5):2418–2428
Scholtes C, Ramiere C, Rainteau D et al (2012) High plasma level of nucleocapsid-free envelope glycoprotein-positive lipoproteins in hepatitis C patients. Hepatology 56(1):39–48
Meunier J-C, Russell RS, Engle RE et al (2008) Apolipoprotein c1 association with hepatitis C virus. J Virol 82(19):9647–9656
Merz A, Long G, Hiet MS et al (2011) Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. J Biol Chem 286(4):3018–3032
Yamamoto M, Aizaki H, Fukasawa M et al (2011) Structural requirements of virion-associated cholesterol for infectivity, buoyant density and apolopoprotein association of hepatitis C virus. J Gen. Virol 92(Pt9):2082–7
Lindenbach BD, Meuleman P, Ploss A et al (2006) Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A 103(10):3805–3809
Gastaminza P, Kapadia SB, Chisari FV (2006) Differential biophysical properties of infectious intracellular and secreted hepatitis C virus particles. J Virol 80(22):11074–11081
Diaz O, Cubero M, Trabaud MA et al (2008) Transmission of low-density hepatitis C viral particles during sexually transmitted acute resolving infection. J Med Virol 80(2):242–246
Bridge SH, Sheridan DA, Felmlee DJ et al (2011) Insulin resistance and low-density apolipoprotein B-associated lipoviral particles in hepatitis C virus genotype 1 infection. Gut 60(5):680–687
Felmlee DJ, Sheridan DA, Bridge SH et al (2010) Intravascular transfer contributes to postprandial increase in numbers of very-low-density hepatitis C virus particles. Gastroenterology 139(5):1774–1783, 1783 e1771-1776
Wojczynski MK, Glasser SP, Oberman A et al (2011) High-fat meal effect on LDL, HDL, and VLDL particle size and number in the Genetics of Lipid-Lowering Drugs and Diet Network (GOLDN): an interventional study. Lipids Health Dis 10:181
Diaz O, Delers F, Maynard M et al (2006) Preferential association of hepatitis C virus with apolipoprotein B48-containing lipoproteins. J Gen Virol 87(Pt 10):2983–2991
Sun HY, Lin CC, Lee JC et al (2012) Very low-density lipoprotein/lipo-viro particles reverse lipoprotein lipase-mediated inhibition of hepatitis C virus infection via apolipoprotein C-III. Gut Jun 11 [Epub ahead of print]
Steenbergen RH, Joyce MA, Lund G et al (2010) Lipoprotein profiles in SCID/uPA mice transplanted with human hepatocytes become human-like and correlate with HCV infection success. Am J Physiol 299(4):G844–G854
Farquhar MJ, Harris HJ, McKeating JA (2011) Hepatitis C virus entry and the tetraspanin CD81. Biochem Soc Trans 39(2):532–536
Evans MJ, von Hahn T, Tscherne DM et al (2007) Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446(7137):801–805
Ploss A, Evans MJ, Gaysinskaya VA et al (2009) Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457(7231):882–886
Lupberger J, Zeisel MB, Xiao F et al (2011) EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 17(5):589–595
Dorner M, Horwitz JA, Robbins JB et al (2011) A genetically humanized mouse model for hepatitis C virus infection. Nature 474(7350):208–211
Sainz B, Jr, Barretto N, Martin DN et al (2012) Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med 18(2) 281–5
Stanford KI, Bishop JR, Foley EM et al (2009) Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice. J Clin Investig 119(11):3236–3245
Goldstein JL, Brown MS (2009) The LDL receptor. Arterioscler Thromb Vasc Biol 29(4):431–438
Williams KJ, Chen K (2010) Recent insights into factors affecting remnant lipoprotein uptake. Curr Opin Lipidol 21(3):218–228
MacArthur JM, Bishop JR, Stanford KI et al (2007) Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members. J Clin Investig 117(1):153–164
Rohrl C, Fruhwurth S, Schreier SM et al (2010) Scavenger receptor, Class B, Type I provides an alternative means for beta-VLDL uptake independent of the LDL receptor in tissue culture. Biochim Biophys Acta 1801(2):198–204
Imagawa M, Takahashi S, Zenimaru Y et al (2012) Comparative reactivity of remnant-like lipoprotein particles (RLP) and low-density lipoprotein (LDL) to LDL receptor and VLDL receptor: effect of a high-dose statin on VLDL receptor expression. Clin Chim Acta; Int J Clin Chem 413(3-4):441–447
Van Eck M, Hoekstra M, Out R et al (2008) Scavenger receptor BI facilitates the metabolism of VLDL lipoproteins in vivo. J Lipid Res 49(1):136–146
Meex SJ, Andreo U, Sparks JD, Fisher EA (2011) Huh-7 or HepG2 cells: which is the better model for studying human apolipoprotein-B100 assembly and secretion? J Lipid Res 52(1):152–158
Ehrhardt M, Leidinger P, Keller A et al (2011) Profound differences of microRNA expression patterns in hepatocytes and hepatoma cell lines commonly used in hepatitis C virus studies. Hepatology 54(3):1112–1113
Bensadoun P, Rodriguez C, Soulier A et al (2011) Genetic background of hepatocyte cell lines: are in vitro hepatitis C virus research data reliable? Hepatology 54(2):748
Barth H, Schnober EK, Zhang F et al (2006) Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J Virol 80(21):10579–10590
Basu A, Kanda T, Beyene A et al (2007) Sulfated homologues of heparin inhibit hepatitis C virus entry into mammalian cells. J Virol 81(8):3933–3941
Molina S, Castet V, Fournier-Wirth C et al (2007) The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J Hepatol 46(3):411–419
Monazahian M, Bohme I, Bonk S et al (1999) Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol 57(3):223–229
Albecka A, Belouzard S, Op de Beeck A et al (2012) Role of LDL receptor in the hepatitis c virus life cycle. Hepatology 55(4):998–1007
Scarselli E, Ansuini H, Cerino R et al (2002) The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 21(19):5017–5025
Catanese MT, Ansuini H, Graziani R et al (2010) Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J Virol 84(1):34–43
Zhang SH, Reddick RL, Piedrahita JA, Maeda N (1992) Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258(5081):468–471
Mamotte CD, Sturm M, Foo JI, van Bockxmeer FM, Taylor RR (1999) Comparison of the LDL-receptor binding of VLDL and LDL from apoE4 and apoE3 homozygotes. Am J Physiol 276(3 Pt 1):E553–E557
Jiang J, Cun W, Wu X et al (2012) Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfate. J Virol 86(13):7256–7267
Owen DM, Huang H, Ye J, Gale M Jr (2009) Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology 394(1):99–108
Mazumdar B, Banerjee A, Meyer K, Ray R (2011) Hepatitis C virus E1 envelope glycoprotein interacts with apolipoproteins in facilitating entry into hepatocytes. Hepatology 54(4):1149–1156
Akazawa D, Morikawa K, Omi N et al (2011) Production and characterization of HCV particles from serum-free culture. Vaccine 29:4821–4828
Liu S, McCormick KD, Zhao W et al (2012) Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding. Hepatology 56(2):484–491
Hishiki T, Shimizu Y, Tobita R et al (2010) Infectivity of hepatitis C virus is influenced by association with apolipoprotein E isoforms. J Virol 84(22):12048–12057
Price DA, Bassendine MF, Norris SN et al (2006) The apolipoprotein e3 allele is associated with persistent hepatitis C virus infection. Gut 55(5):715–718
Wong-Staal F, Syder AJ, McKelvy JF (2010) Targeting HCV entry for development of therapeutics. Viruses 2(8):1718–1733
Anderson LJ, Lin K, Compton T, Wiedmann B (2011) Inhibition of cyclophilins alters lipid trafficking and blocks hepatitis C virus secretion. Virol J 8:329
Gastaminza P, Dryden KA, Boyd B et al (2010) Ultrastructural and biophysical characterization of hepatitis C virus particles produced in cell culture. J Virol 84(21):10999–11009
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is a contribution to the special issue on Immunopathology of viral hepatitis - Guest Editor: C. Selmi and J. Vierling
Rights and permissions
About this article
Cite this article
Bassendine, M.F., Sheridan, D.A., Bridge, S.H. et al. Lipids and HCV. Semin Immunopathol 35, 87–100 (2013). https://doi.org/10.1007/s00281-012-0356-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00281-012-0356-2